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ABSTRACT
Objective: The current investigation for antidiabetic activity of the plant Vernonia divergens (DC.) Edgew. has not been reported till date. However, to 
enlighten the folkloric claim of the plant, the study was carried out on various animal models such as albino mice, albino rabbits, Wistar rats, rabbits, 
hamsters, dogs, and monkeys.
Methods: The whole plant of V. divergens was studied on various animal models. Screening methods generally have been carried out on rodents and 
non-rodents, respectively. Various biochemical and hematological parameters such as serum glucose, plasma insulin, lipid profile and activities of liver 
enzymes, red blood cells, white blood cells, hemoglobin, and differential counts were measured to assess the antihyperglycemic and antihyperlipidemic 
activities as well as safety profile of the extract.
Results: Among all experimental extracts of V. divergens, it was found that the aqueous and methanolic extracts had maximum control of blood glucose 
in diabetic Wistar rats. While comparing with normoglycemic animals, it was observed that reduction of blood sugar level and increase in plasma 
insulin level are maximum with test extract. Among the study, the effects of the methanolic extract of V. divergens (MEVD) and aqueous extract of 
V. divergens (AEVD) were done through oral route in both the models, i.e., normoglycemic and hyperglycemic animal models. The safety profile was 
evaluated by toxicological evaluation and observed that, even at a higher dose level of 3000 mg/kg body weight, the MEVD and AEVD were safe and 
retain normal physiological and behavioral effect. The whole protein, whole cholesterol, aspartate aminotransferase, alanine aminotransferase, and 
alkaline phosphatase enzyme activity of streptozotocin-administered rats showed significantly higher than normal rats, and the test extract-treated 
rats significantly reduced the elevated levels.
Conclusion: It is concluded that the MEVD and AEVD (DC.) Edgew. might be beneficial in effectively reducing the blood glucose concentration and 
managing the various complications of diabetes. However, in comparison between both the extracts, the methanol extract was found to be significantly 
more potent than that of the A.E. in all aspects.
Keywords: Vernonia divergens (DC.) Edgew., Normoglycemic, Hyperglycemic, Wistar rats.
INTRODUCTION
The term diabetes mellitus (DM) describes as a metabolic cum 
vascular syndrome of more than one etiology characterized by chronic 
hyperglycemia with resultant abnormalities in metabolism of protein fat 
and carbohydrate ensuing from impaired secretion and defected action 
of insulin or both. The outcomes of DM include long-term casualty, 
i.e., damage, dysfunction, and failure of several organs. DM may represent 
with attribute signs and symptoms such as polyphagia, polydipsia, 
polyurea, blurring of vision, and weight loss [1]. This is affecting nearly 
25% of the population [2]. The prevalence of diabetes according to the 
World Health Organization projections is likely to increase by 35% [3]. 
Currently, the incidence of diabetes is nearly 150 million globally, and 
by the year 2025, this is likely to increase to 300 million or more [3,4]. 
While reviewing the statistical projection status of India, we can come 
across the fact that the incidence of diabetics is increasing and will rise 
from 15 million in 1995 to reach up to 57 million in the year 2025 which 
can make the country highest prevalent of diabetics worldwide [3]. 
Therefore, it is necessary to look for new solutions to manage this health 
problem. Many herbal products have been described for DM in ancient 
literature of Ayurveda in India [5]. The belief in traditionally used herbal 
drugs for curing various disease state is very strong in Nigeria and many 
other poor African countries [6,7].
India is one of the highest populated diabetogenic countries. In human 
population, DM remains one of the major contributors among all 
other diseases. Due to enhancing awareness now-a-days the concern 
of medicinal plant in health care system is increasing and interest 
in local plant remedies for treating of various disease is growing in 
many developed as well as developing countries. Vernonia divergens 
is commonly known as insulin plant having a potent effect against 
glucose reduction belonging to family Asteraceae which is used as an 
outstanding drug for DM described earlier [8]. Thus, the rationale of the 
present study was to ascertain the truth of the claim about antidiabetic 
activity on the plant V. divergens (DC.) Edgew. so that novel compound 
against the treatment of diabetes can be identified.
METHODS
Collection and authentication of plant
The plant V. divergens appears in the month of March and November. 
The whole plant was collected from Keonjhar district, a forest at Daitari, 
field No. 1, (Odisha). Before their use, they were carefully identified by 
Dr. Pratap Chandra Panda, Principal Scientist, Regional Plant Resource 
Centre, Bhubaneswar.
Preparation of plant extracts
The plants collected were dried at room temperature by the method of 
shade drying. The plants were spreaded over a polythene cover under 
fan. After drying, pulverizing was done with the help of mechanical 
grinder to get the powder form of plant material. The powder was then 
passed through a fine mesh sieve to get a fine powder. The powdered 
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material (600 g) was extracted with different solvents separately 
of non-polar to polar, for example, petroleum ether (pet. ether), 
chloroform, methanol, and water by the help of Soxhlet apparatus. The 
liquid extracts were concentrated under vacuum to yield dry extracts 
and preserved in a desiccator until further experiments.
Percentage yield of the extracts
The percentage yield of the plant V. divergens was found to be 2.66%, 
1.66%, 14.66%, and 12.66% with pet. ether, chloroform, methanol, and 
water, respectively. The percentage yield of the methanolic extract of 
V. divergens (MEVD) was found to be greater (14.66%) than extracts 
with other solvents.
Preparation of drug solution
The semisolid extracts of V. divergens were dissolved in sufficient 
quantity of solvent (tween and normal saline), and the aqueous 
extracts (A.Es) were dissolved in normal saline for administration. 
Glibenclamide 5 mg/kg was dissolved in a sufficient quantity of normal 
saline and used in the treatment [9]. Streptozotocin 40 mg/kg was 
dissolved in the buffer solution and used to induce diabetes in rats [10].
Selection of animals
For both toxicological and antidiabetic assessments, adult Wistar albino 
rats of healthy status weighing about 150–200 g were selected after 
getting the Institutional Animal Ethics Committee approval (Approval 
No-10/15/SPS/IAEC/SOAU). The selected animals have been housed 
in acrylic cages in well-known environmental conditions (temperature: 
20–25°C and relative humidity: 45–55% under 12 h light/dark cycle). 
To acclimate the laboratory condition, animals were fed with standard 
rodent diet for 1 week and water ad libitum [11].
Induction of diabetes
In the present study, a single dose of streptozotocin 40 mg/kg in normal 
saline was administered intraperitoneally [10]. After 1 week assessment 
of gradual development, diabetes was done. For the determination of 
blood glucose concentration, an experiment was performed on the 7th 
day. The animals with blood glucose levels between 200 and 250 mg/dl 
were chosen for antidiabetic screening and they were considered as 
diabetic rats.
Experimental procedure
The study was carried out as mentioned below to check whether the 
MEVD is acting as an insulin secretagogue (stimulation of insulin 
secretion from the pancreatic β-cell and to check the utilization) 
activity as well as to check whether the MEVD possesses antidiabetic 
activity and hypoglycemic activity.
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Analytical procedure
Blood sample was drawn into tubes at different time intervals. 
Serum was separated out by centrifugation and used in different 
estimations. Diabetes was induced by a single dose of Streptozotocin 
administration. Blood glucose level, which is elevated in association 
with hyperglycemia, was measured to assess whether the plant extract 
has antidiabetic/hypoglycemic effect. To estimate plasma insulin level 
insulin kit was used. Radioimmunoassay was performed by employing 
double antibody technique to get the final result [12]. A significant body 
weight reduction is associated with diabetes hence the body weight was 
recorded before, during and after the treatment. Acute toxic study was 
performed to find out toxic symptoms of the extract and gross behavioral 
changes were also noticed. Sub-acute toxicity study was performed to 
reveal the influence of the extract on biochemical, hematological and 
histopathological findings. Alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP) etc. were 
assayed in serum. Serum lipids like total cholesterol (TC), high density 
lipoprotein (HDL), Low density lipoprotein (LDL), Very LDL (VLDL) 
and triglyceride (TG) were estimated. Serum total protein and albumin 
were analyzed. Blood parameters like hemoglobin (Hb), red blood 
cells (RBC), white blood cells (WBC) etc. counts were determined. 
Clotting time was also determined.
Toxicity studies
Acute toxicity studies
To rule out any toxicity of the extracts, acute oral toxicity test was 
performed on 12 h fasted healthy Wistar albino rats according to the 
principles of Organization for economic co-operation and development 
(OECD) (OECD guidelines 423) [13]. This study was performed with 
the major aim of therapeutic index establishment and also for the 
purpose of primary screening. Therapeutic index meant the ratio of 
pharmacologically effective dose to the lethal dose. A group of 10 mice 
have been fasting overnight was administered the A.E. of V. divergens 
(AEVD) once orally at 4 dose levels (500, 1000, 2000, 3000 mg/kg). The 
initial observation of test drug treated mice was continuously recorded 
and then further reading was taken occasionally for 4 h. Final recording 
of overnight mortality was done [14]. In the course of duration of 
study, spontaneous activity reduction and behaviors of the mice were 
attentively observed [15].
Sub-acute toxicity studies
The purpose of this study is to determine the maximum tolerated dose 
and daily dose for 3–4 weeks and to indicate the nature of toxic reaction 
of the drug. In present study, the influence of V. divergens extract on 
hematological parameters, a pathological change on 21 days dosing in 
streptozotocin induce diabetic rats were carried out. The diabetic rats were 
grouped into 6 groups of 6 animals each. Group I animals received solvent, 
Group II animals received standard drug, Group III (100 mg/kg body 
weight) and Group IV (200 mg/kg body weight) was received MEVD and 
Group V (100 mg/kg body weight) and Group VI (200 mg/kg body weight) 
was received AEVD once daily for 21 days. At the end of the experimental 
period the blood was collected, serum was separated and subjected to 
hematological and biochemical examination [14].
Statistical analysis
The values are represented as mean ± standard error mean. The data 
obtained from various studies were subjected to one-way analysis 
of variance (ANOVA) [16]. Dunnett’s t-test was also performed after 
ANOVA for establishing statistical significance.
RESULTS
In Table 1 Preliminary antidiabetic effect of various extracts of V. divergens 
on single dose treated diabetic rats induced by streptozotocin was 
shown. It revealed that pet. ether, chloroform, M.E. and A.E. registered 
6.81%, 16.50%, 52.76% and 33.25% decrease in fasting blood glucose 
levels respectively at the dose level of 100 mg/kg in oral route at the end 
of 8 h. However at the same time solvent control (distilled water) and 
pet. ether showed gradual increase in blood sugar level. The standard 
drug glibenclamide 5 mg/kg possess 72.84% decrease in blood glucose 
level at same duration. The A.E. significantly decreases the blood sugar 
level at the end of 4 h and 8 h in the level of p<0.01, while the methanol 
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extract (M.E.) showed significant decrease of blood sugar level starting 
from 2 h to the end of 8 h at the level of p<0.05 to p<0.001 with respect 
to solvent control. However the standard drug caused decrease of blood 
sugar level beginning from 1 h (p<0.05) up to 8 h (p<0.001) when 
compared with solvent.
Table 2 summarizes that the M.E. and A.E. at the dose level of 100 mg/kg 
and 200 mg/kg registered 19.33% and 30.72% and 14.54% and 25.08% 
reduction in glucose concentration of blood after 4 h, respectively, while 
the standard drug glibenclamide (5 mg/kg) reduces blood glucose level 
up to 48.20% at the same time. At the end of 4 h, the test extracts at 
two dose levels bear a significant (p<0.001) decrease of blood glucose 
compared to solvent control, while the standard drug holds the same 
significance (p<0.001) from the beginning of 2 h.
The data recorded in Table 3 showed that the M.E. and A.E. possess 
25.79% and 36.81% and 19.44% and 33.31% decrease in blood glucose 
level at the dose level of 100 mg/kg and 200 mg/kg, respectively, by 
oral route at the end of 8 h, while the standard drug registered 48.45% 
reduction at the same time. However, the solvent control group showed 
a negligible reduction of blood glucose level at the end of 8 h. The two 
extracts at the dose level of 100 mg/kg showed a significant decrease 
(p<0.01) at 8 h, and at the same time, the dose level 200 mg/kg showed 
more significant (p<0.001) when compared to solvent control.
The result expressed in Table 4 revealed that the M.E. and A.E. in the dose 
level of 100 mg/kg and 200 mg/kg possess 48.54% and 55.00% and 
34.10% and 50.09% reduction in the blood glucose level, respectively, 
at the end of 8 h, while the standard drug registered 65.03% decrease 
in blood sugar level at the same time.
Table 5 shows the hypoglycemic effect of MEVD and AEVD on multidose 
treated normoglycemic rats. The purpose of the study is to establish 
the therapeutic validity of the test extracts in long-term use. The data 
showed that there was a decrease in blood sugar level to the extent of 
25.56% and 34.14% in case of M.E. and 19.14% and 30.09% in case of 
A.E. at the dose level of 100 mg/kg and 200 mg/kg, respectively, on the 
21st day of treatment.
The purpose of antidiabetic study is to confirm the antidiabetic effect of the 
test extracts on longer duration of treatment, and the data are shown in 
Table 6. The M.E. and A.Es are registered 50.68% and 57.68% and 40.55% 
Table 1: Preliminary antidiabetic effect of various extracts of Vernonia divergens on single dose treated streptozotocin‑induced diabetic rats
Group and treatment Blood glucose levels (mg/dl)
0 h 1 h 2 h 4 h 8 h % decrease at the end of 8 h
Solvent (tween+water) 251.2±11.5 256.5±11.3 274.3±9.3 278.7±8.4 282.3±8.4 -
Standard glibenclamide (5 mg/kg) 274.3±13.9 201.2±11.6c 149.2±9.0c 101.7±9.6c 74.5±4.6c 72.84
Pet. ether extract (100 mg/kg) 266.7±11.4 275.3±11.9 264.3±10.9 254.7±9.2 248.5±6.5c 6.81
Chloroform extract (100 mg/kg) 264.3±11.7 253.2±9.8 243.3±9.6 224.5±8.9c 220.7±6.2c 16.50
Methanol extract (100 mg/kg) 259.7±11.6 241.2±9.6 200.5±9.7c 148.3±10.9c 122.7±6.4c 52.76
Aqueous extract (100 mg/kg) 271.7±13.8 261.2±11.6 223.5±10.3b 192.3±9.6c 181.3±7.9c 33.25
F values 1.31 5.36** 21.94** 49.04** 133.62**
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01 and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, Pet. ether: Petroleum ether
Table 2: OGTT of MEVD and AEVD in single dose treated glucose‑loaded hyperglycemic rats
Group and treatment Blood glucose levels (mg/dl) 
60 min 0 h 1 h 2 h 4 h % decrease at the end of 4 h
Solvent (tween+water) 104.2±4.6 107.5±4.1 123.3±2.4 136.5±2.0 102.3±2.6 –
Standard glibenclamide (5 mg/kg) 104.5±4.4 90.2±3.8 78.7±2.7c 66.5±2.9c 54.2±2.7c 48.20
MEVD (100 mg/kg) 104.3±4.5 102.2±2.4 92.5±2.7c 88.7±2.9c 84.16±2.1c 19.33
MEVD (200 mg/kg) 104.7±4.3 95.3±2.1b 84.2±2.2c 78.2±2.4c 72.5±2.4c 30.72
AEVD (100 mg/kg) 105.5±4.0 104.5±3.9 98.5±2.8c 93.3±2.8c 90.2±2.8b 14.54
AEVD (200 mg/kg) 105.7±3.9 99.3±2.8 90.7±2.5c 85.2±2.2c 79.3±1.8c 25.08
F value 3.63* 37.14** 89.25** 45.30**
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). OGTT: Oral 
glucose tolerance test, SEM: Standard error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia 
divergens
Table 3: Hypoglycemic effect of MEVD and AEVD on single dose treated normoglycemic rats
Group and treatment Blood glucose levels (mg/dl) 
0 h 1 h 2 h 4 h 8 h % decrease at the end of 8 h
Solvent (tween+water) 103.3±2.4 103.7±2.0 104.3±2.2 106.3±2.4 105.2±1.8 –
Standard glibenclamide (5 mg/kg) 102.2±2.9 90.5±3.1b 81.7±2.5c 74.3±1.2c 52.7±1.3c 48.45
MEVD (100 mg/kg) 104.7±2.8 104.5±2.2 97.2±1.9a 94.2±1.9c 77.7±2.7c 25.79
MEVD (200 mg/kg) 102.3±2.4 102.5±2.4 95.5±1.4b 85.3±1.5c 64.7±1.5c 36.81
AEVD (100 mg/kg) 103.7±2.7 103.2±2.5 99.5±1.5a 96.2±1.3b 83.5±4.5c 19.44
AEVD (200 mg/kg) 103.7±1.2 103.5±1.2 96.7±1.4a 90.2±1.6c 70.2±2.1c 32.31
F value 1.05 5.31** 16.56** 39.97** 54.81**
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens
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and 52.59% of decrease of blood glucose level at the tested dose level of 
100 mg/kg and 200 mg/kg, respectively, on the 21st day of treatment, while 
the standard drug showed 60.81% reduction on the same day.
Plasma insulin levels significantly (p<0.001) increased in case of both 
M.E. and A.Es at both 100 mg/kg and 200 mg/kg dose level. Both 
extracts at both the dose level indicated a rise in insulin concentration of 
133.43 and 173.37 and 126.51 and 156.16 µU/ml, respectively, on 14th 
day, while standard drug glibenclamide showed highest concentration 
of plasma insulin, i.e., 181.94 µU/ml at the end of 14th day and the data 
are depicted in Table 7.
The content of Table 8 indicated that there was a decrease in 
percentage loss of body weight when measured on 3rd, 7th, 14th, and 21st 
Table 4: Antidiabetic activity of MEVD and AEVD in single dose treated streptozotocin‑induced diabetic rats
Group and treatment Blood glucose levels (mg/dl) 
0 h 1 h 2 h 4 h 8 h % decrease at the end of 8 h
Solvent (tween+water) 252.5±10.6 258.7±10.2 272.7±9.4 288.5±8.9 297.7±7.1 –
Standard glibenclamide (5 mg/kg) 273.2±11.4 259.3±9.7 219.2±8.2c 129.7±6.6c 95.5±5.5c 65.03
MEVD (100 mg/kg) 263.3±9.7 254.7±9.5 226.3±8.8b 171.2±5.9c 135.5±4.4c 48.54
MEVD (200 mg/kg) 261.2±9.5 245.6±10.1 211.7±9.0c 148.3±6.1c 117.5±6.4c 55.00
AEVD (100 mg/kg) 273.7±10.2 266.2±10.3 246.5±8.6 200.6±5.5c 180.3±5.3c 34.10
AEVD (200 mg/kg) 271.5±9.7 258.7±9.6 227.3±8.8b 168.7±5.9c 135.5±4.1c 50.09
F value 0.38 0.46 6.37** 72.31** 171.09**
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens
Table 5: Hypoglycemic effect of MEVD and AEVD on multidose treated normoglycemic rats
Group and treatment Blood glucose levels (mg/dl) 
Day 0 Day 7 Day 14 Day 21 % decrease at the end of day 21
Solvent (tween+water) 104.2±2.2 104.8±2.4 104.7±2.1 105.5±2.6 –
Standard glibenclamide (5 mg/kg) 106.2±2.9 86.16±2.8c 68.5±2.7c 52.3±2.0c 50.70
MEVD (100 mg/kg) 104.3±2.5 101.5±2.2 93.3±2.4b 77.7±2.6c 25.56
MEVD (200 mg/kg) 104.5±2.4 98.2±2.5 84.7±2.9c 68.5±2.0c 34.34
AEVD (100 mg/kg) 105.3±2.5 103.5±2.2 97.5±2.0 85.16±2.1c 19.14
AEVD (200 mg/kg) 104.7±2.3 100.3±2.1 89.7±1.9 73.2±2.2c 30.09
F value 8.09** 27.59** 60.61**
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens
Table 6: Antidiabetic activity of MEVD and AEVD on multidose treated streptozotocin‑induced diabetic rats
Group and treatment Blood glucose levels (mg/dl) 
Day 0 Day 3 Day 7 Day 14 Day 21 % decrease at the end of day 21
Solvent (tween+water) 275.3±4.2 265.5±4.1 253.7±4.1 238.5±6.1 238.5±6.1 −
Standard glibenclamide (5 mg/kg) 274.3±3.6 227.2±4.2c 182.5±4.2c 156.3±4.4c 107.5±4.3c 60.81
MEVD (100 mg/kg) 279.2±4.2 263.3±4.0 233.2±5.4a 186.2±4.2c 137.7±4.2c 50.68
MEVD (200 mg/kg) 280.5±3.8 261.7±4.8 226.2±4.7b 173.2±3.1c 118.7±4.5c 57.69
AEVD (100 mg/kg) 278.7±4.7 272.2±3.3 250.7±5.1 210.2±4.7a 165.7±4.2c 40.55
AEVD (200 mg/kg) 279.5±4.3 267.7±4.3 230.7±5.1b 181.5±4.7c 132.5±4.2c 52.59
F value 0.36 15.63*** 28.44*** 40.13*** 108.00***
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-Value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens
Table 7: Effect of MEVD and AEVD on plasma insulin levels in streptozotocin‑induced diabetic rats
Group and treatment Plasma insulin level (µU/ml)
Day 0 Day 7 Day 14 Day 21
Solvent (tween+water) 22.66±3.75 21.28±2.80 26.87±3.54 23.58±2.79
Standard glibenclamide (5 mg/kg) 33.84±3.67c 169.95±11.61c 181.94±9.58c 113.86±7.59c
MEVD (100 mg/kg) 23.56±2.87b 94.38±9.58c 133.43±11.49c 115.29±9.13c
MEVD (200 mg/kg) 32.89±3.51c 154.18±11.83c 173.37±10.53c 121.93±8.19c
AEVD (100 mg/kg) 24.36±3.73b 89.66±7.56c 126.5±9.14c 113.58±9.41c
AEVD (200 mg/kg) 32.66±2.65c 145.51±12.53c 156.16±10.25c 117.84±6.23c
F value 3.61* 44.34** 73.21** 87.32**
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens
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days of treatment in both tested dose levels. The M.E. at 100 mg/kg 
possesses 6.72% loss of body weight on 21st day, while on the 3rd day, 
the percentage loss of body weight registered 12%. Similarly at a dose 
level of 200 mg/kg on 21st day measured 5.55% and on 3rd day 10% loss 
of body weight. The A.E. at 100 mg/kg possesses 7.42% loss of body 
weight on 21st day, while on the 3rd day, the percentage loss of body 
weight registered 11%. Similarly at dose level of 200 mg/kg on 21st day 
measured 5.8% and on 3rd day 10% loss of body weight.
The data presented in Table 9 demonstrated that the glycogen content 
of the liver and kidney of DM animals treated with M.E. and A.Es of 
leaves of V. divergens and standard drug was significantly increased 
when compared with solvent control after the completion of 21 days of 
drug exposure, even the test extracts and standard drug approach the 
content of glycogen toward normal level.
The data observed in Table 10 present a significant (p<0.01) reduction 
of TC in serum in the groups treated with test extraction and standard 
drug when compared with solvent control. The extent of reduction in 
both the close level of test extracts was dose dependent. In case of TGs, 
there was a significant reduction with both test extract and standard 
drug when compared with solvent control on the 21st day of treatment. 
The value of HDL in case of test extract at tested dose levels and 
standard drug showed significant increase than that of solvent control 
group, while the LDL and VLDL levels significantly (p<0.001) decrease 
in all drug-treated groups when compared with solvent control.
The hematological parameters exhibited in Table 11 show that the 
animals treated with standard drug glibenclamide and test extracts 
in the tested dose levels bear normal in RBC count and Hb, whereas 
the clotting time slightly elevated. However, the diabetic rats treated 
with solvent showed a decrease value of RBC, WBC, and Hb. The 
neutrophil count appears to nearly equal with that of normal value. The 
other hematological parameters such as eosinophil, lymphocyte, and 
monocytes in case of the standard drug and test extract-treated animals 
did not show any alteration.
From Table 12, it was observed that AST and ALT enzyme activity of 
streptozotocin-induced diabetic rats was significantly higher than 
normal rats. The test extracts and treated rats at tested dose had 
reduced enzyme activity when compared with diabetic rats. The total 
protein and albumin content of serum was significantly lowered in 
diabetic rats when compared with solvent control, but in the drug-
treated diabetic animals, it returned to nearly normal.
DISCUSSION
Diabetes is a chronic disease that occurs when either insulin deficiency 
or resistance or both exists. The hyperglycemic condition causes 
increased glycosylation leading to various complications such as 
neuropathy, retinopathy, nephropathy, and cardiomyopathy [17]. 
The present study was carried out to investigate and validate the 
antidiabetic activity of the plant V. divergens (DC.) Edgew. The blood 
glucose lowering property of MEVD and AEVD is comparable with 
the standard drug glibenclamide (5 mg/kg body weight). Among the 
tested extract, the M.E. and A.E. at the dose level of 100 mg/kg possess a 
marked reduction in blood glucose level through oral route. Therefore, 
the M.E. and A.E. were selected for the evaluation of hypoglycemic 
and/or antidiabetic activity. It is observed that the MEVD and AEVD 
effectively control the glucose concentration of blood in normoglycemic 
as well as hyperglycemic rats in single unit dose treated model. The 
background mechanism of such effect might be due to a decrease in 
the initial absorption rate when glucose and plant fiber given together 
orally [18]. Hence, it may be presumed that the glucose lowering effect 
Table 8: Percentage loss of body weight in MEVD and AEVD in 
streptozotocin‑induced diabetic rats
Group and treatment Percentage loss of body weights
Day 3 Day 7 Day 14 Day 21
Solvent (tween+water) 10 16 18.66 25.33
Standard glibenclamide
 (5 mg/kg)
8 6.66 6.66 3.33
MEVD (100 mg/kg) 12 10.11 8.0 6.72
MEVD (200 mg/kg) 10 8.23 6.38 5.55
AEVD (100 mg/kg) 11 10.15 9.0 7.42
AEVD (200 mg/kg) 10 8.15 6.66 5.8
The values indicating the percentage loss in body weights are calculated 
from the mean body weights of animals (n=6), in the respective groups 
on the respective days. MEVD: Methanolic extract of Vernonia divergens, 
AEVD: Aqueous extract of Vernonia divergens
Table 9: Effect of MEVD and AEVD on the glycogen concentration 
in the liver and kidney









MEVD (100 mg/kg) 28.46±1.19* 13.60±2.20
MEVD (200 mg/kg) 31.80±4.40** 15.67±1.67
AEVD (100 mg/kg) 27.66±2.65* 12.60±2.06
AEVD (200 mg/kg) 30.16±2.72** 14.5±1.19
F value 5.09b 3.10a
Values are explicated in the form of mean±SEM. To analyze the statistical 
significance Dunnett’s t-test and one-way ANOVA were executed. (F-Value 
indicates statistical significance at *p˂0.05, **p˂0.01. t-value stands for 
statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when 
compared to Group I). SEM: Standard error mean, ANOVA: Analysis of variance, 
MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of 
Vernonia divergens
Table 10: Effect of MEVD and AEVD on lipid profile in subacute toxicity
Group and treatment Lipid profile
TC (mg/dl) TG (mg/dl) HDL (mg/dl) LDL (mg/dl) VLDL (mg/dl) 
Solvent (tween+water) 226.8±5.4 180.0±6.7 34.2±4.1 162.8±6.3 42.7±3.0
Standard glibenclamide (5 mg/kg) 160.3±4.7c 101.8±3.1c 46.7±3.3a 84.7±5.3c 23.8±2.6c
Normal 137.8±4.1 87.2±1.7 50.7±3.3 65.2±4.7 17.2±3.0
MEVD (100 mg/kg) 194.2±4.1 134.8±5.0b 38.2±4.6 134.7±5.1 31.7±2.4a
MEVD (200 mg/kg) 185.5±5.5b 114.3±4.6c 40.2±3.5 114.8±4.1b 28.3±2.1b
AEVD (100 mg/kg) 205.2±5.0 145.5±5.1 36.5±5.4 148.2±5.4 35.8±3.1
AEVD (200 mg/kg) 191.7±4.1 124.3±5.0 39.6±4.1 129.7±4.7 30.2±3.0
F value 56.27** 54.53** 2.76* 57.79** 13.51**
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens, TC: Total cholesterol, 
TG: Triglyceride, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, VLDL: Very low-density lipoprotein
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of the extract was achieved by an extraintestinal action. The two extracts 
at the dose level of 100 mg/kg showed a significant decrease (p<0.01) 
in blood glucose at 8 h, while at the same time, the dose level 200 mg/kg 
showed more significant (p<0.001) when compared to solvent control. 
The test extracts showed a significant decrease (p<0.001) of blood 
glucose level starting from 4 h onward in the tested dose levels, while 
standard drug possesses the same rate of significance beginning from 
2 h while compared with solvent control. The observed data results 
of the experiments suggested that both the MEVD and AEVD are able 
to maintain the hypoglycemic effect up to 21st day and no behavioral 
changes are observed during the treatment periods.
This study further supports the antidiabetic effect of the test extracts 
whose effectiveness persists up to 21 days and the blood sugar level 
decreases gradually during the observed days, which presumed that 
the test extracts contain some antidiabetic active principle responsible 
for this effect. The hypoglycemic active principle acts by initiating the 
release of insulin from the pancreatic cell of hyperglycemic animal 
(sulfonylurea like effect) [19]. The proper mechanism of action is 
further supported by oral glucose tolerance test, in which glucose level 
reduces in the response of test extract. While insulin level concerned 
in comparison with standard drug, it was observed that there was an 
increased plasma insulin level and hence concluded the insulinotropic 
effect [11]. Therefore, it is credible that glucose-lowering properties 
of the extracts strive a direct effect in hyperglycemic rat probably 
by a similar mechanism to insulin which was substantiated by an 
extrapancreatic mode of action. The experiment revealed that M.E. and 
A.E. of V. divergens (200 mg/kg) significantly (p<0.001) decrease the 
glucose level on hyperglycemic animal. The glucose lowering activity 
observed in the diabetic animal may be due to the stimulation of β-cells 
in the pancreatic islets.
It has been reported that diabetes is a heterogeneous metabolic 
disorder, in which one of the symptomatic characters is loss in body 
weight [20]. It has been stated that DM results deficiency to glucose 
utilization for energy leads to increased utilization & decreased storage 
of proteins. By the above-stated reason, depletion of protein takes 
place resulting in reduced body weight [21]. The results of the study 
presented that the decreased loss of body weight might be contributed 
by increased use of glucose by the tissue.
The glycogen content of the liver and kidney of DM animals treated with 
M.E and A.E of leaves of V. divergens and standard drug was significantly 
increased when compared with solvent control after the completion of 
21 days of treatment, even the test extracts and standard drug approach 
the content of glycogen toward normal glycogen level. It was reported 
that hyperglycemia results in decreased glucose utilization and glycogen 
synthesis [22]. The glycogen content in the liver and kidney increases 
in the extract-treated group compared to the diabetic rats indicating 
participation of the extract components in glycogen synthesis similar 
to insulin [23]. Dyslipidemia is a known complication associated with 
diabetes [24]. The abnormally high concentration of serum TG, TC, 
LDL, and low HDL observed in diabetic rats compared to control rats 
is in consonant with reports from previous studies [24-27], indicating 
that an increase in glucose level on induction of diabetes results in an 
equivalent rise in blood lipids. It has been reported that, in the diabetic 
patients those are untreated or under treatment, hypertriglyceridemia 
and hypercholesterolemia often occur due to the increased generation 
of VLDL and deficiency of lipoprotein lipase [28]. The result revealed 
that the test extract reduces VLDL, TC and TG actively. Hence, it might 
be surmised that, similar to insulin, the test extract is the prime cause 
for the endowment of the transcription of lipoprotein lipase.
The result of hematological parameters evidenced that the test 
extracts have no significant effect on the same and is evident for the 
safely used at the MEVD and AEVD for a longer duration time. The 
experimental approach has been conducted for the test extracts to 
elicit tonic response over an exposure period of 21 days’ alteration 
in the marker enzymes such as AST, ALT, and ALP. The data obtained 
from this study also indicated that the MEVD significantly decreased 
Table 12: Effect of MEVD and AEVD on biochemical parameters in subacute toxicity
Group and treatment AST (µl) ALT (µl) ALP (µl) Albumin (g/dl) Total Protein (g/dl)
Solvent (Tween+water) 36.16±3.8 48.67±4.1 290.50±4.5 5.82±0.8 4.76±0.8
Standard glibenclamide (5 mg/kg) 25.17±3.2a 30.34±2.3b 270.84±4.9a 4.20±0.8 6.26±1.0
Normal 22.84±3.9 28.34±3.4 262.17±6.1 3.40±0.4 8.08±0.5
MEVD (100 mg/kg) 35.84±3.9 38.84±3.0a 282.17±5.0 5.16±0.8 5.18±0.8
MEVD (200 mg/kg) 30.67±3.1 34.67±2.2b 276.16±4.5a 4.70±0.7 5.66±0.7
AEVD (100 mg/kg) 37.66±3.4 39.84±3.9 284.33±6.1 5.66±0.7 5.01±0.6
AEVD (200 mg/kg) 32.16±3.2 35.67±2.3 278.66±5.1a 4.90±0.8 5.33±0.5
F value 3.66* 7.14** 4.65** 1.61 2.68*
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA were executed. (F-value indicates 
statistical significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). 
SEM: Standard error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens, AST: Aspartate 
aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase
Table 11: Effect of MEVD and AEVD on hematological parameters in subacute toxicity
















Solvent (tween+water) 2.7±0.4 7.9±0.9 7.3±1.5 1.4±0.01 21.2±3.7 4.7±0.7 72.7±4.5 4.5±0.7
Standard glibenclamide 
(5 mg/kg)
4.9±0.6a 6.9±1.1 10.6±1.2 1.1±0.08 27.8±2.3 1.9±0.5c 69.8±3.3 2.7±0.7
Normal 5.2±0.6 7.2±1.2 11.8±1.4 1.1±0.07 32.7±1.5 1.5±0.07 68.7±3.3 1.8±0.2
MEVD (100 mg/kg) 3.7±0.8 6.2±0.4 8.3±1.5 1.4±0.07 24.3±2.1 2.5±0.3b 71.4±4.1 3.3±0.9
MEVD (200 mg/kg) 4.6±0.7 6.6±0.7 8.8±1.2 1.3±0.07 26.2±1.6 2.1±0.4b 70.3±3.9 3.1±0.3
AEVD  (100 mg/kg) 3.1±1.0 5.9±1.1 8.2±1.1 1.4±0.8 23.1±1.1 2.7±0.7 71.7±3.5 3.9±0.6
AEVD (200 mg/kg) 4.1±0.5 6.4±0.9 8.5±1.2 1.3±0.7 25.2±1.2 2.3±0.2 70.8±3.3 3.2±0.5
F value 2.8* 1.05 2.02 3.88* 3.2* 8.50** 0.95 2.17
Values are explicated in the form of mean±SEM. To analyze the statistical significance, Dunnett’s t-test and one-way ANOVA was executed. (F-value indicates statistical 
significance at *p˂0.05, **p˂0.01. t-value stands for statistical significance at ap<0.05, bp<0.01, and cp<0.001, respectively, when compared to Group I). SEM: Standard 
error mean, ANOVA: Analysis of variance, MEVD: Methanolic extract of Vernonia divergens, AEVD: Aqueous extract of Vernonia divergens, RBC: Red blood cells, 
WBC: White blood cells
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the levels of AST, ALT, and ALP. The increased activity of transaminases, 
which are active in the absence of insulin due to increased availability of 
amino acids in diabetes, is believed to be responsible for the increased 
gluconeogenesis and ketogenesis observed in the disease [29]. Alanine 
and aspartate transaminase activities are used as an indicator of 
hepatocyte damage [30]. Elevation of serum ALP concentration in 
patients with DM has been observed for several years, but the source 
and reasons are unknown [31].
CONCLUSION
The findings of the current study indicated that MEVD and AEVD may 
get a place in the treatment of DM as hypoglycemic and/or antidiabetic 
agent. The MEVD and AEVD (DC.) Edgew. might be beneficial in 
effectively reducing the blood glucose concentration and managing of 
various complications of diabetes. However, in comparison between 
both the extracts, the M.E. was found to be significantly more potent 
than that of the A.E. in all aspects. Clinical studies are required to 
establish whether the administration of MEVD and AEVD can potentiate 
the antidiabetic effect of conventional agents.
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